Skip to main content
. 2015 Jan 20;5(23):11957–11970. doi: 10.18632/oncotarget.2566

Figure 4. (A) Impact of multiple-injection treatments on MBL-II-141 plasma levels at 1 h or 4 h after the last injection.

Figure 4

MBL-II-141 was administered at 10 mg/kg to SCID mice by IP injection one, two or three times separated by 4 h intervals. Blood was withdrawn for HPLC-MS/MS analysis at 1 h or 4 h after the last injection (N = 6 mice/group). (B) Comparison of the route administration. MBL-II-141 at 10 mg/kg was administered by either IP injection or force-feeding. The results correspond to plasma levels observed 4 h after the administration (N = 7 mice/group). One value from the force-feeding treatment group was considered as an outlier by the R software, and so not considered in the analysis.